scholarly journals Replacement of neuraminidase inhibitor-susceptible influenza A(H1N1) with resistant phenotype in 2008 and circulation of susceptible influenza A and B viruses during 2009-2013, South Africa

2018 ◽  
Vol 13 (1) ◽  
pp. 54-63 ◽  
Author(s):  
Florette K. Treurnicht ◽  
Amelia Buys ◽  
Stefano Tempia ◽  
Mpho Seleka ◽  
Adam L. Cohen ◽  
...  
Keyword(s):  
South Africa ◽  
Influenza A ◽  
Neuraminidase Inhibitor ◽  
Resistant Phenotype ◽  
Influenza A H1n1

scholarly journals Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan

2013 ◽  
Vol 7 (6) ◽  
pp. 1390-1399 ◽  
Author(s):  
Emi Takashita ◽  
Seiichiro Fujisaki ◽  
Noriko Kishida ◽  
Hong Xu ◽  
Masaki Imai ◽  
...  
Keyword(s):  
Influenza A ◽  
Neuraminidase Inhibitor ◽  
Four Seasons ◽  
Influenza A H1n1

scholarly journals Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza A(H1N1) viruses, Germany, 2007-8

2010 ◽  
Vol 15 (6) ◽  
Author(s):  
U Buchholz ◽  
S Brockmann ◽  
S Duwe ◽  
B Schweiger ◽  
M an der Heiden ◽  
...  
Keyword(s):  
Influenza A ◽  
Case Control Study ◽  
Neuraminidase Inhibitor ◽  
Case Control ◽  
P Value ◽  
Influenza B ◽  
Travel History ◽  
Influenza A H1n1 ◽  
Nested Case Control ◽  
Control Study

During the influenza season 2007-8, the proportion of seasonal influenza A(H1N1) viruses resistant to the neuraminidase inhibitor oseltamivir increased worldwide. We conducted an investigation to compare patients infected with oseltamivir-resistant (ose-R) and oseltamivir- susceptible (ose-S) influenza A(H1N1) viruses regarding risk factors for resistance and the capability to transmit in the household setting. Within a cohort of 396 laboratory confirmed influenza patients from sentinel physicians we conducted a nested case-control study among patients infected with A(H1N1). Thirty patients in the cohort were infected with influenza B, none with influenza A(H3N2) and 366 with A(H1N1). Of the 366 A(H1N1) viruses 52 (14%) were ose-R. Demographic characteristics, oseltamivir exposure, travel history and outcome were not significantly different between ose-S and ose-R patients. Among 133 households in the nested case-control study, secondary household attack rates in households with ose-R cases and households with ose-S cases were similar (23 versus 26%; p-value=0.54). Ose-R household status and occurrence of secondary cases were associated with an odds ratio of 0.85 (95% confidence interval 0.38-1.88). We conclude that seasonal ose-R influenza A(H1N1) viruses have transmitted well in the household setting.

scholarly journals Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice

2008 ◽  
Vol 53 (2) ◽  
pp. 791-793 ◽  
Author(s):  
Mariana Baz ◽  
Yacine Abed ◽  
Benjamin Nehmé ◽  
Guy Boivin
Keyword(s):  
Influenza A ◽  
Neuraminidase Inhibitor ◽  
H1n1 Influenza ◽  
Mortality Rates ◽  
Wild Type Virus ◽  
Type Virus ◽  
Wild Type ◽  
H1n1 Influenza Virus ◽  
Influenza A H1n1 ◽  
Virus Mutant

ABSTRACT The new oral neuraminidase (NA) inhibitor A-322278 was evaluated in mice infected with influenza A/H1N1 wild-type virus or the oseltamivir-resistant (H274Y mutant) virus. A-322278 decreased mortality rates and lung virus titers significantly more than oseltamivir in mice infected with the NA H274Y mutant when therapy was started 4 h before or even 48 h after infection.

scholarly journals High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa

QJM ◽  
2010 ◽  
Vol 103 (5) ◽  
pp. 319-325 ◽  
Author(s):  
C. F. N. Koegelenberg ◽  
E. M. Irusen ◽  
R. Cooper ◽  
A. H. Diacon ◽  
J. J. Taljaard ◽  
...  
Keyword(s):  
South Africa ◽  
Respiratory Failure ◽  
High Mortality ◽  
Influenza A ◽  
Influenza A H1n1

Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada

2011 ◽  
Vol 50 (3) ◽  
pp. 257-261 ◽  
Author(s):  
Jean Longtin ◽  
Samir Patel ◽  
Alireza Eshaghi ◽  
Ernesto Lombos ◽  
Rachel Higgins ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
Neuraminidase Inhibitor ◽  
Resistance Testing ◽  
Influenza A H1n1 ◽  
Inhibitor Resistance

scholarly journals Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection

2010 ◽  
Vol 54 (6) ◽  
pp. 2575-2582 ◽  
Author(s):  
Norio Sugaya ◽  
Yasuo Ohashi
Keyword(s):  
Virus Infection ◽  
Influenza A ◽  
H1n1 Virus ◽  
Controlled Trial ◽  
Influenza Virus Infection ◽  
Neuraminidase Inhibitor ◽  
Double Blind ◽  
Influenza A H1n1 ◽  
B Virus ◽  
Long Acting

ABSTRACT We conducted a double-blind, randomized controlled trial to compare a long-acting neuraminidase inhibitor, laninamivir octanoate, with oseltamivir. Eligible patients were children 9 years of age and under who had febrile influenza symptoms of no more than 36-h duration. Patients were randomized to 1 of 3 treatment groups: a group given 40 mg laninamivir (40-mg group), a group given 20 mg laninamivir (20-mg group), and an oseltamivir group. Laninamivir octanoate was administered as a single inhalation. Oseltamivir (2 mg/kg of body weight) was administered orally twice daily for 5 days. The primary end point was the time to alleviation of influenza illness. The primary analysis included 184 patients (61, 61, and 62 in the 40-mg group, 20-mg group, and oseltamivir group, respectively). Laninamivir octanoate markedly reduced the median time to illness alleviation in comparison with oseltamivir in patients infected with oseltamivir-resistant influenza A (H1N1) virus, and the reductions were 60.9 h for the 40-mg group and 66.2 h for the 20-mg group. On the other hand, there were no significant differences in the times to alleviation of illness between the laninamivir groups and oseltamivir group for patients with influenza A (H3N2) or B virus infection. Laninamivir octanoate was well tolerated. The most common adverse events were gastrointestinal events. Laninamivir octanoate was an effective and well-tolerated treatment for children with oseltamivir-resistant influenza A (H1N1) virus infection. Further study will be needed to confirm clinical efficacy against influenza A (H3N2) or B virus infection. Its ease of administration is noteworthy, because a single inhalation is required during the course of illness.

scholarly journals Impact of outpatient neuraminidase inhibitor treatment on hospitalisation in patients infected with influenza A (H1N1)pdm09: An IPD analysis

2016 ◽  
Vol 45 ◽  
pp. 248 ◽  
Author(s):  
S. Venkatesan ◽  
P.R. Myles ◽  
J. Leonardi-Bee ◽  
P. Consortium Investigators ◽  
J.S. Nguyen-Van-Tam
Keyword(s):  
Influenza A ◽  
Neuraminidase Inhibitor ◽  
Influenza A H1n1 ◽  
Inhibitor Treatment
Sign in / Sign up

Export Citation Format

Share Document